Indian Pharma Market grew by 10% in February to Rs.10,762 cr

Posted on Updated on


The Indian Pharmaceutical Market has achieved a double digit growth of 10 per cent during the month of February 2019, slightly lower than the growth in January 2019 of 11.3 per cent as the respiratory and dermatology segments shown lower growth of 3.8 per cent and 9.8 per cent respectively. According to AIOCD-AWACS report, anti-infectives achieved growth of 4.6 per cent and Vitamins sales moved up by 9.9 per cent. All the chronic therapies including anti-diabetic notched up a high double digit growth of 16.1 per cent while Cardio grew by 15.9 per cent and CNS by 13.6 per cent during February 2019. Indian companies grew by 10.2 per cent and MNCs are growing slightly lower at 10 per cent.

The volumes are not showing encouraging upward trend for last three months. Growth Driver’s (GD) as volumes remained at 2.7 per cent and price increase of 4.9 per cent. Based on MAT GDs volumes worked out to 4.2 per cent and prices at 3.1 per cent. FDC related market showed negative growth of 50.5 per cent while the non FDC market showed a growth of 10.6 per cent. The single molecules grew at 10.3 per cent during February 2019. Price component of GD for the FDCs is 1.7 per cent, other GDs in terms of volumes are at negative 52.4 per cent while new products contributed only 0.1 per cent. The non FDC component growth drivers see volumes at 2.3 per cent, prices at 5.8 per cent while new products are growing at 2.6 per cent.

Among the top 50 corporate, 46 registered positive growth of IPM. Amongst the top 10 corporates, Torrent has the highest growth at 19.8 per cent followed by Lupin at 16.6 per cent and Intas at 15.3 per cent. Further, Ipca Laboratories registered growth of 32.5 per cent, followed by Micro growth at 16 per cent ans Sanofi moved up by 14 per cent. Abbott HC clocked growth of 3 per cent and Abbott India achieved growth of 15.9 per cent. Sun Portfolio has shown a growth of 7.4 per cent, while Ranbaxy also slower at 6.8 per cent. Emcure got a double digit growth of 10.5 per cent while Zuventus moved up faster at 16.7 per cent. Total 8 companies launched during last three years. Amongst the top 60 MNCs Boehringer Ingelheim achieved highest growth of 28.6 per cent followed by Bayer Zydus at 20.1 per cent and Sanofi at 14 per cent.

The NLEM 2013 containing molecules market showed growth at 6.2 per cent to Rs.1055 crore whereas the non NLEM market grew at 10.4 per cent to Rs.9,245 crore resulting in an overall growth of 10 per cent during February 2018.

From the therapy perspective, 19 therapies have shown a positive growth during February 2019. During the month Respiratory market moved up by 3.8 per cent, Derma at 9.8 per cent, Gastrointestinal by 8.7 per cent. Pain and analgesics achieved growth of 10.8 per cent and VMN 9.9 per cent. All the 31 regions have posted positive growth. Bihar market grew the highest by 22.3 per cent followed by MP growing at 19.4 per cent and Odissa growing at 19.3 per cent.

Amoxycillin plus clavulanic acid market grew by single digit growth of 8.1 per cent to Rs.189 crore and glimepiride plus metformin market achieved double digit growth rate of 12.1 per cent. Glimepiride plus metformin was pegged at 185 crore. Azilsartan plain market is now valued at Rs.73 crore on MAT basis. Sofosbuvir and its combination market has reached at Rs.760 crore on MAT basis. The luliconazole market is worth Rs.388 crore and tenegliptin and its combinations are valued at 880 crore on MAT basis. The market of paracetamol plain registered a double digit growth rate of 14.7 per cent on monthly basis and plain atorvastatin has posted a growth of 9.4 per cent. Montelukast polus levocetrizine has slowed down at 6.9 per cent. Voglibose plus metformin plus glimepiride has posted a double digit growth of 23.9 per cent.

Maxtard has posted monthly sales of Rs.41 crore, followed by Glycomemt GP at Rs.36 crore, Lantus at Rs.42 crore and Galvus met at Rs.35 crore. Liv 52 market reached at Rs.32 crore and that of Janumet capture sales of Rs.41 crore. Augmentin reached at Rs.37 crore. New launches Azilsartan and combinations are now valued at Rs.27 crore with launch of total 34 brands. There are 64 brands launched in last 24 months in the Luliconazole segment and these new launches are worth Rs.99 crore on MAT basis. Among the VMS category total 12 brands were launched during February 2019 and within cardiac there have been 4 brands.

Source: 1

Let us know what you think!

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s